Public Health

Area of Science:

• Gerontology
• Pharmacology
• Neuroscience

Background:

• Dipeptidyl peptidase 4 inhibitors (DPP-4i) are common antidiabetic drugs with potential neuroprotective effects.
• The impact of DPP-4i on cognitive function in older adults with type 2 diabetes (T2D) remains unclear.

Purpose of the Study:

• To investigate the association between DPP-4 inhibitor use and cognitive function changes in elderly T2D patients.
• To analyze the impact of DPP-4i on memory, attention, executive functions, and semantic categorization.

Main Methods:

• Longitudinal study of non-demented T2D adults (≥65 years) from the Israel Diabetes and Cognitive Decline (IDCD) cohort.
• Analysis of electronic health records for antidiabetic medication use, classifying exposure to DPP-4i.
• Linear mixed-effects models adjusted for confounders to assess cognitive changes over time.

Main Results:

• No significant differences in global cognition, attention, executive function, or semantic categorization were found between DPP-4i users and non-users.
• A trend towards slower memory decline was observed in the DPP-4i group (p=0.06).
• Memory score divergence was noted in individuals over 70 years old.

Conclusions:

• DPP-4i use was not significantly associated with overall cognitive function changes in this T2D cohort.
• A potential trend of preserved memory function warrants further investigation.
• Larger sample sizes and longer follow-up periods are needed to confirm these findings.